Literature DB >> 6097262

Chemistry of the inhibitors of the renin-angiotensin system.

R Geiger.   

Abstract

The enzyme renin splits a single peptide bond in the plasma glycoprotein angiotensinogen liberating the biologically inactive decapeptide angiotensin I (ANG I). A second enzyme, angiotensin converting enzyme (CE), releases the strong vasoconstricting octapeptide ANG II via degradation of a C-terminal dipeptide. The effect of this compound on blood pressure can be attenuated by interference with the enzyme-controlled peptide cascade of the renin-angiotensin system (RAS). This is accomplished by inhibition of renin and CE, respectively. Orally active CE inhibitors are valuable drugs in the treatment of renal and essential hypertension and of heart failure. Strong inhibitors of renin have also been synthesized, however, peptide moieties which have still to be present in these compounds impede oral absorption. Finally, antagonistic analogues of ANG II are able to block its effect on the receptor level. Their application is limited by the still existing partial agonistic activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097262

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  Mnemogenic effects of injecting RA-octil, a CE-inhibitor derivate, systemically or into the basal forebrain.

Authors:  P Gerhardt; R U Hasenöhrl; F J Hock; J P Huston
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

2.  Converting enzyme inhibitor ramipril stimulates prostacyclin synthesis by isolated rat aorta: evidence for a kinin-dependent mechanism.

Authors:  H Scherf; R Pietsch; G Landsberg; H J Kramer; R Düsing
Journal:  Klin Wochenschr       Date:  1986-08-15

3.  Studies on the effect of two angiotensin-converting enzyme inhibitors, captopril and cilazapril, on platelet and vascular prostaglandin metabolism in vivo.

Authors:  B Wagner; H G Eichler; B Schneider; B Blöchl-Daum; B Brenner; S Gasic; K Lechner; P A Kyrle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-10       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.